The markets cannot seem to catch a breather, find a glimpse of hope, or even come close to ending the day flat. Even Healthcare has been getting beaten up recently. Recessionary proof? I do not feel anything is recessionary proof in this current environment. The Healthcare Select Sector SPDR, (XLV: 27.60, 0.00 (0.00%)), is down 22.54% year to date, not quite near the Financials SPDR, XLF down 47.18%, but still more than ever expected in a bear market. So, where does that leave an investor like you trying to find that bottom, time it right, and catch huge on the upside? Well, I won’t necessarily provide you with that information because I think we still have quite a long way to go before we can recover. However, I will provide you a staple holding to your portfolio. No, not something like a Wal-Mart (WMT: 54.44, 0.00 (0.00%)), Protor and Gamble (PG: 64.10, 0.00 (0.00%)), or a CVS Pharmacies (CVS: 29.61, 0.00 (0.00%)), that is actually a staples company. I am referring to Johnson & Johnson.  You might think that JNJ is a very unoriginal thought and possibly a no-brainer to anyone who is diversifying a portfolio; but, many people have strayed away from it because of its Pharmaceutical exposure.  Investors forget it’s nice dividend (2.9% yield), but not as high yielding compared to its competitors like Pfizer (PFE: 17.13, 0.00 (0.00%)) (7.3% yield), Bristol Meyers Squibb (BMY: 18.70, 0.00 (0.00%)) (6.6% yield), Sanofi-Aventis (SNY: 28.59, 0.00 (0.00%)) (5.3% yield), and Merck (MRK: 29.13, 0.00 (0.00%)) (5% yield) just to name a few.

So why JNJ?

Why not is the real question? Personally, I wish I had invested in July. I know I wouldn’t have seen any appreciation but being flat right now that’s really all you can ask for as an equity investor. JNJ operates in three major segments: Pharmaceuticals, Medical Devices and Diagnostics, and Consumer.